Cipla Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Cipla reported consolidated revenue from operations of ₹28,162.59 Crores for FY26, up 2.2% from ₹27,547.62 Crores in FY25. However, consolidated profit after tax declined 27% to ₹3,861.74 Crores from ₹5,269.20 Crores in the prior year. The decline was primarily due to an exceptional item of ₹275.91 Crores arising from new labour code implementation (increase in gratuity and leave liabilities), plus ₹42.02 Crores impairment of investment in associates. The company recommended a final dividend of ₹13 per equity share. Auditors issued an unmodified (clean) opinion. Cipla also completed acquisition of Inzpera Healthsciences Limited for ₹110.65 Crores in December 2025, creating goodwill of ₹66.70 Crores. A contingent liability of ₹2,011 Crores related to NPPA drug pricing disputes remains disclosed but no provision has been made.
The 27% decline in PAT despite modest revenue growth is a concern, though much of it stems from a one-time labour code charge. The clean audit opinion and dividend declaration provide some comfort, but investors will watch for recovery in profitability going forward.